Muscle & nerve · 2025
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Developing During Tacrolimus Treatment: A Case Series.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Evans Matthew C, Bellanti Roberto, Dahdaleh Samer, Karunaratne Kushan, Rinaldi Simon, Pritchard Jane, Viegas Stuart
Аннотация
INTRODUCTION/AIMS: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) can occasionally emerge during treatment with tacrolimus, a commonly used immunosuppressant for solid organ transplantation, and this association is poorly recognized. We describe the clinical presentation, investigations, and disease course of a series of patients who developed CIDP during tacrolimus treatment.
METHODS: This is a retrospective case series of six patients with electrophysiologically confirmed CIDP (=2021 EFNS/PNS criteria) during tacrolimus use for solid organ transplantation, evaluated at two UK National Health Service (NHS) trusts between 2017 and 2023. We describe the clinical characteristics, laboratory investigations, neurophysiological features, treatment response, and association with tacrolimus treatment.
RESULTS: CIDP was diagnosed between 5 months and 13 years after initiation of tacrolimus, post cardiac (2), renal (2), lung (1), and combined kidney-pancreas (1) transplantation. All patients met diagnostic criteria for CIDP. 5/6 patients improved clinically following intravenous immunoglobulin (IVIg). 4/6 patients were switched to either sirolimus or azathioprine without evidence of active disease despite no further treatment. 2/6 patients continued tacrolimus, and both required ongoing IVIg treatment.
DISCUSSION: CIDP may be associated with tacrolimus use in organ transplantation and can occur after years of treatment. IVIg was usually effective in our cohort, and in those who switched to alternative immunosuppression, there was no evidence of active disease after initial treatment.
METHODS: This is a retrospective case series of six patients with electrophysiologically confirmed CIDP (=2021 EFNS/PNS criteria) during tacrolimus use for solid organ transplantation, evaluated at two UK National Health Service (NHS) trusts between 2017 and 2023. We describe the clinical characteristics, laboratory investigations, neurophysiological features, treatment response, and association with tacrolimus treatment.
RESULTS: CIDP was diagnosed between 5 months and 13 years after initiation of tacrolimus, post cardiac (2), renal (2), lung (1), and combined kidney-pancreas (1) transplantation. All patients met diagnostic criteria for CIDP. 5/6 patients improved clinically following intravenous immunoglobulin (IVIg). 4/6 patients were switched to either sirolimus or azathioprine without evidence of active disease despite no further treatment. 2/6 patients continued tacrolimus, and both required ongoing IVIg treatment.
DISCUSSION: CIDP may be associated with tacrolimus use in organ transplantation and can occur after years of treatment. IVIg was usually effective in our cohort, and in those who switched to alternative immunosuppression, there was no evidence of active disease after initial treatment.